Please Wait.....
Report
Roche Diagnostics International Ltd - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Operational KPI's, and Recent Trends
Company Report I 2025-05-14 I 102 Pages I Quaintel Research
Report Summary
Roche Diagnostics International Ltd - Strategic SWOT Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence and Operational KPI's, and Recent Trends is a comprehensive and easily accessible overview of Roche Diagnostics International Ltd 's business operations. It provides a detailed analysis of the company's strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Roche Diagnostics International Ltd including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Roche Diagnostics International Ltd's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. By integrating these strategic analyses, the report offers a comprehensive understanding of Roche Diagnostics International Ltd's overall strategic standing and supports informed decision-making and strategic planning.
Finally, the report includes recent news and deal activities undertaken by Roche Diagnostics International Ltd enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Roche Diagnostics International Ltd, founded in 1896, is a core division of the global healthcare company Roche Group. Headquartered in Rotkreuz, in the canton of Zug, Switzerland, the company plays a central role in Roche's worldwide diagnostics business. It is strategically positioned to support all major operational functions, including research and development, production, logistics, marketing, and technical services, making it a vital component of Roche's innovation ecosystem.
As part of the Roche Group, which has a presence in more than 100 countries, Roche Diagnostics International Ltd contributes significantly to the global availability of diagnostic solutions. The Rotkreuz site alone employs over 2900 individuals representing more than 75 nationalities, making it the largest private-sector employer in the region. The company focuses on delivering high-quality in vitro diagnostic solutions, including molecular diagnostics, clinical chemistry, immunoassays, point-of-care testing, and laboratory automation systems, all designed to improve patient care through timely and accurate disease detection.
Roche Diagnostics International Ltd in the News:-
- 29-Oct-2024 - Roche is investing 215 million in the Rotkreuz site and is building an innovative production building
- 10-Sep-2024 - Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
- 19-Dec-2023 - Roche to increase its payroll in Switzerland by 2,0 percent
- 27-Oct-2023 - [Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche's Vabysmo for the treatment of retinal vein occlusion (RVO)
- 19-Oct-2023 - Roche reports good sales growth despite decline in demand for COVID-19 products
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the Roche Diagnostics International Ltd's internal and external factors through SWOT analysis and Corporate Strategy.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Roche Diagnostics International Ltd:
- Roche Diagnostics International Ltd PESTLE Analysis
- Roche Diagnostics International Ltd Value Chain Analysis
- Roche Diagnostics International Ltd Porter's Five Forces Analysis
- Roche Diagnostics International Ltd VRIO Analysis
- Roche Diagnostics International Ltd BCG Analysis
- Roche Diagnostics International Ltd Segmentation, Targeting and Positioning (STP) Analysis
- Roche Diagnostics International Ltd Ansoff Matrix Analysis
Table of Contents
Table of Contents 2
Tables 6
Charts 7
Roche Diagnostics International Ltd - Key Company Facts 8
Roche Diagnostics International Ltd - Company Description 9
Roche Diagnostics International Ltd - Top Executives 10
Roche Diagnostics International Ltd - Top Executives Biographies 11
Roche Diagnostics International Ltd - Head Office & Locations 13
Head Office - Country 13
Key Subsidiaries 14
Roche Diagnostics International Ltd - Products and Services 16
Products 16
Services 17
Roche Diagnostics International Ltd - Historic Events 18
Roche Diagnostics International Ltd - Company's Mission and Vision 20
Mission 20
Roche Diagnostics International Ltd - Corporate Strategy 21
Roche Diagnostics International Ltd - Business Description 23
Core Laboratory Solutions 23
Molecular Diagnostics 24
Point of Care Diagnostics 24
Diabetes Care 24
Tissue Diagnostics 25
Sequencing and Life Science Research 25
Roche Diagnostics International Ltd - ESG Spotlight 26
Environment 26
Social 27
Corporate Governance 27
Roche Diagnostics International Ltd - SWOT Analysis 28
Overview 28
Strengths 30
Weaknesses 32
Opportunities 33
Threats 35
Competing Players 36
Snapshot of Competing Players 37
Abbott Laboratories 37
Key Company Facts 37
Company Description 37
Abbott Laboratories - SWOT Spotlight 38
Abbott Laboratories - PESTLE Spotlight 40
Key Financials 42
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 42
Key Financial Ratio Analysis 47
GSK plc 48
Key Company Facts 48
Company Description 48
GSK plc - SWOT Spotlight 49
GSK plc - PESTLE Spotlight 51
Key Financials 53
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 53
Key Financial Ratio Analysis 58
Johnson & Johnson Services, Inc. 59
Key Company Facts 59
Company Description 59
Johnson & Johnson Services, Inc. - SWOT Spotlight 60
Johnson & Johnson Services, Inc. - PESTLE Spotlight 62
Key Financials 64
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 64
Key Financial Ratio Analysis 69
Pfizer Inc. 70
Key Company Facts 70
Company Description 70
Pfizer Inc. - SWOT Spotlight 71
Pfizer Inc. - PESTLE Spotlight 73
Key Financials 75
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 75
Key Financial Ratio Analysis 80
Thermo Fisher Scientific Inc. 81
Key Company Facts 81
Company Description 81
Thermo Fisher Scientific Inc. - SWOT Spotlight 82
Thermo Fisher Scientific Inc. - PESTLE Spotlight 84
Key Financials 86
Share Price Trend - Jan-2024 to May-2025 (Average Share Closing Price) 86
Key Financial Ratio Analysis 91
Roche Diagnostics International Ltd - In the News 92
29-Oct-2024 - Roche is investing 215 million in the Rotkreuz site and is building an innovative production building 92
10-Sep-2024 - Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation 93
19-Dec-2023 - Roche to increase its payroll in Switzerland by 2,0 percent 94
27-Oct-2023 - [Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche's Vabysmo for the treatment of retinal vein occlusion (RVO) 94
19-Oct-2023 - Roche reports good sales growth despite decline in demand for COVID-19 products 94
18-Oct-2023 - Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns 94
18-Oct-2023 - Roche's Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer 95
13-Oct-2023 - Late-breaking data for Roche's BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis 95
12-Oct-2023 - New data for Roche's OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided 95
11-Oct-2023 - Roche's OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions 96
10-Oct-2023 - Roche's Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies 96
04-Oct-2023 - Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche's Evrysdi able to sit independently after 1 year of treatment 96
02-Oct-2023 - Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD 96
Roche Diagnostics International Ltd - Key Deals 97
23-Jan-2024 - Research collaboration between Roche, the University Hospital Zurich and the University of Zurich to explore the value of data sharing for oncology patients 97
23-Oct-2023 - Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant 98
24-Jul-2023 - Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk 98
22-Mar-2023 - Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease 99
13-Dec-2022 - Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options 99
11-May-2022 - Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure 99
01-Dec-2021 - Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases 99
Appendix 100
Definitions 100
SWOT Analysis 100
PESTLE Analysis 100
Value Chain Analysis 100
ESG Spotlight 100
Research Methodology 101
Disclaimer 102
Contact Us 102
Tables
Table 1: Roche Diagnostics International Ltd - Company Facts
Table 2: Roche Diagnostics International Ltd - Digital Presence
Table 3: Roche Diagnostics International Ltd - Top Executives
Table 4: Roche Diagnostics International Ltd - Top Executives Biographies
Table 5: Roche Diagnostics International Ltd - Subsidiaries
Table 6: Roche Diagnostics International Ltd - Products
Table 7: Roche Diagnostics International Ltd - Services
Table 8: Roche Diagnostics International Ltd - Historic Events
Table 9: Roche Diagnostics International Ltd - Competing Players
Table 10: Competing Players - Abbott Laboratories - Key Company Facts
Table 11: Abbott Laboratories - Share Price Trend - Jan-2024 to May-2025
Table 12: Competing Players - Abbott Laboratories - Profit and Loss Statement
Table 13: Abbott Laboratories - Balance Sheet 2021-2024
Table 14: Abbott Laboratories - Cash Flow Statement 2021-2024
Table 15: Abbott Laboratories - Ratio Analysis - 2021-2024
Table 16: Competing Players - GSK plc - Key Company Facts
Table 17: GSK plc - Share Price Trend - Jan-2024 to May-2025
Table 18: Competing Players - GSK plc - Profit and Loss Statement
Table 19: GSK plc - Balance Sheet 2021-2024
Table 20: GSK plc - Cash Flow Statement 2021-2024
Table 21: GSK plc - Ratio Analysis - 2021-2024
Table 22: Competing Players - Johnson & Johnson Services, Inc. - Key Company Facts
Table 23: Johnson & Johnson Services, Inc. - Share Price Trend - Jan-2024 to May-2025
Table 24: Competing Players - Johnson & Johnson Services, Inc. - Profit and Loss Statement
Table 25: Johnson & Johnson Services, Inc. - Balance Sheet 2022-2024
Table 26: Johnson & Johnson Services, Inc. - Cash Flow Statement 2022-2024
Table 27: Johnson & Johnson Services, Inc. - Ratio Analysis - 2022-2024
Table 28: Competing Players - Pfizer Inc. - Key Company Facts
Table 29: Pfizer Inc. - Share Price Trend - Jan-2024 to May-2025
Table 30: Competing Players - Pfizer Inc. - Profit and Loss Statement
Table 31: Pfizer Inc. - Balance Sheet 2021-2024
Table 32: Pfizer Inc. - Cash Flow Statement 2021-2024
Table 33: Pfizer Inc. - Ratio Analysis - 2021-2024
Table 34: Competing Players - Thermo Fisher Scientific Inc. - Key Company Facts
Table 35: Thermo Fisher Scientific Inc. - Share Price Trend - Jan-2024 to May-2025
Table 36: Competing Players - Thermo Fisher Scientific Inc. - Profit and Loss Statement
Table 37: Thermo Fisher Scientific Inc. - Balance Sheet 2021-2024
Table 38: Thermo Fisher Scientific Inc. - Cash Flow Statement 2021-2024
Table 39: Thermo Fisher Scientific Inc. - Ratio Analysis - 2021-2024
Charts
Figure 1: Roche Diagnostics International Ltd - SWOT Analysis
Figure 2: Competing Players - Abbott Laboratories - SWOT Spotlight
Figure 3: Competing Players - Abbott Laboratories - PESTLE Spotlight
Figure 4: Abbott Laboratories - Average Share Price Trend - Jan-2024 to May-2025
Figure 5: Abbott Laboratories - Profit and Loss Statement - 2021-2024
Figure 6: Abbott Laboratories - Balance Sheet - 2021-2024
Figure 7: Abbott Laboratories - Cash Flow Statement 2021-2024
Figure 8: Competing Players - GSK plc - SWOT Spotlight
Figure 9: Competing Players - GSK plc - PESTLE Spotlight
Figure 10: GSK plc - Average Share Price Trend - Jan-2024 to May-2025
Figure 11: GSK plc - Profit and Loss Statement - 2021-2024
Figure 12: GSK plc - Balance Sheet - 2021-2024
Figure 13: GSK plc - Cash Flow Statement 2021-2024
Figure 14: Competing Players - Johnson & Johnson Services, Inc. - SWOT Spotlight
Figure 15: Competing Players - Johnson & Johnson Services, Inc. - PESTLE Spotlight
Figure 16: Johnson & Johnson Services, Inc. - Average Share Price Trend - Jan-2024 to May-2025
Figure 17: Johnson & Johnson Services, Inc. - Profit and Loss Statement - 2022-2024
Figure 18: Johnson & Johnson Services, Inc. - Balance Sheet - 2022-2024
Figure 19: Johnson & Johnson Services, Inc. - Cash Flow Statement 2022-2024
Figure 20: Competing Players - Pfizer Inc. - SWOT Spotlight
Figure 21: Competing Players - Pfizer Inc. - PESTLE Spotlight
Figure 22: Pfizer Inc. - Average Share Price Trend - Jan-2024 to May-2025
Figure 23: Pfizer Inc. - Profit and Loss Statement - 2021-2024
Figure 24: Pfizer Inc. - Balance Sheet - 2021-2024
Figure 25: Pfizer Inc. - Cash Flow Statement 2021-2024
Figure 26: Competing Players - Thermo Fisher Scientific Inc. - SWOT Spotlight
Figure 27: Competing Players - Thermo Fisher Scientific Inc. - PESTLE Spotlight
Figure 28: Thermo Fisher Scientific Inc. - Average Share Price Trend - Jan-2024 to May-2025
Figure 29: Thermo Fisher Scientific Inc. - Profit and Loss Statement - 2021-2024
Figure 30: Thermo Fisher Scientific Inc. - Balance Sheet - 2021-2024
Figure 31: Thermo Fisher Scientific Inc. - Cash Flow Statement 2021-2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security